Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.46 |
| ▸ | MDM4 | O15151 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410927 | 1.00 | CASP3 (0.46) | CASP3MDM4TP53KMT2APTPN1 | |
| SCHEMBL2197679 | 0.97 | CASP3 (0.48) | CASP3MDM4TP53KMT2APTPN1 | |
| SCHEMBL2197673 | 0.97 | CASP3 (0.48) | CASP3MDM4TP53KMT2APTPN1 | |
| SCHEMBL2193899 | 0.95 | CASP3 (0.43) | CASP3MDM4TP53KMT2APTPN1 | |
| SCHEMBL2193892 | 0.95 | CASP3 (0.43) | CASP3MDM4TP53KMT2APTPN1 | |
| SCHEMBL2199171 | 0.95 | PTPN1 (0.44) | CASP3MDM4TP53PTPN1 | |
| SCHEMBL2199165 | 0.95 | PTPN1 (0.44) | CASP3MDM4TP53PTPN1 | |
| SCHEMBL17446680 | 0.92 | MDM4 (0.47) | CASP3MDM4TP53KMT2A | |
| SCHEMBL3669368 | 0.92 | CASP3 (0.45) | CASP3MDM4TP53PTPN1 | |
| SCHEMBL1770805 | 0.92 | CASP3 (0.40) | CASP3MDM4TP53KMT2APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888097-B1 | FK 228 DERIVATES AS HDAC INHIBITORS | UNIV SOUTHAMPTON (GB) | 2014-03-05 | — | — | EP | disclosed |
| US-8614193-B2 | Depsipeptides and their therapeutic use | KARUS THERAPEUTICS LIMITED (GB) | 2013-12-24 | — | — | US | disclosed |
| EP-2293846-B1 | Depsipeptides and their therapeutic use | KARUS THERAPEUTICS LTD (GB) | 2013-07-10 | — | — | EP | disclosed |
| US-7977304-B2 | FK 228 derivates as HDAC inhibitors | UNIVERSITY OF SOUTHAMPTON HIGHFIELD (GB) | 2011-07-12 | — | — | US | disclosed |
| US-20110112090-A1 | Depsipeptides and Their Therapeutic Use | KARUS THERAPEUTICS LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| EP-2293846-A1 | DEPSIPEPTIDES AND THEIR THERAPEUTIC USE | Karus Therapeutics Limited (GB) | 2011-03-16 | — | — | EP | disclosed |
| WO-2010116173-A1 | DEPSIPEPTIDES AND THEIR THERAPEUTIC USE | KARUS THERAPEUTICS LIMITED (GB) | 2010-10-14 | — | — | WO | disclosed |
| WO-2009141658-A1 | DEPSIPEPTIDES AND THEIR THERAPEUTIC USE | KARUS THERAPEUTICS LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| US-20090131390-A1 | FK 228 derivates as HDAC inhibitors | UNIVERSITY OF SOUTHAMPTON (GB) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131390-A1 | FK 228 derivates as HDAC inhibitors | HDAC1, HDAC8, HDAC11 | CASP3 466/4885MDM4 2959/4885TP53 1672/4885 |
| US-20110112090-A1 | Depsipeptides and Their Therapeutic Use | PRLHR, OPRD1, NPR3 | CASP3 1509/4885MDM4 4621/4885TP53 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.